Identification of fluorescence in situ hybridization assay markers for prediction of disease progression in prostate cancer patients on active surveillance

BMC Cancer
Katerina PestovaStephen K Van Den Eeden

Abstract

Prostate Cancer (PCa) is the second most prevalent cancer among U.S. males. In recent decades many men with low risk PCa have been over diagnosed and over treated. Given significant co-morbidities associated with definitive treatments, maximizing patient quality of life while recognizing early signs of aggressive disease is essential. There remains a need to better stratify newly diagnosed men according to the risk of disease progression, identifying, with high sensitivity and specificity, candidates for active surveillance versus intervention therapy. The objective of this study was to select fluorescence in situ hybridization (FISH) panels that differentiate non-progressive from progressive disease in patients with low and intermediate risk PCa. We performed a retrospective case-control study to evaluate FISH biomarkers on specimens from PCa patients with clinically localised disease (T1c-T2c) enrolled in Watchful waiting (WW)/Active Surveillance (AS). The patients were classified into cases (progressed to clinical intervention within 10 years), and controls (did not progress in 10 years). Receiver Operating Characteristic (ROC) curve analysis was performed to identify the best 3-5 probe combinations. FISH parameters were the...Continue Reading

References

Oct 9, 2001·Epidemiologic Reviews·G J Miller, K C Torkko
Jun 17, 2003·Journal of Cell Science·Jeffrey M Levsky, Robert H Singer
Jul 25, 2003·The New England Journal of Medicine·William G NelsonWilliam B Isaacs
Oct 29, 2005·Science·Scott A TomlinsArul M Chinnaiyan
Jul 20, 2007·Oncogene·G AttardUNKNOWN Transatlantic Prostate Group
Oct 25, 2008·Annual Review of Medicine·Danil V MakarovAlan W Partin
Jul 15, 2009·Prostate Cancer and Prostatic Diseases·K MwamukondaG Petrovics
Jan 28, 2010·British Journal of Cancer·A H M ReidUNKNOWN Transatlantic Prostate Group
Apr 6, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jeffrey J TosoianH Ballentine Carter
Nov 8, 2012·Nature Reviews. Urology·Lara K BoydYong-Jie Lu
Jan 21, 2014·European Urology·Stacy LoebRuth Etzioni
Jan 15, 2015·Journal of the National Comprehensive Cancer Network : JNCCN·Ayal A AizerPaul L Nguyen
Mar 31, 2015·International Journal of Cancer. Journal International Du Cancer·Katy J L BellPaul Glasziou
Oct 29, 2015·The New England Journal of Medicine·Joaquin MateoJohann S de Bono
Dec 30, 2015·North American Journal of Medical Sciences·Shikha JaiswalKomal Sarmad
Jan 28, 2016·Nature Reviews. Urology·Sophie M BruinsmaUNKNOWN Movember GAP3 consortium
Mar 10, 2016·Nature Reviews. Urology·Jeffrey J TosoianStacy Loeb
Apr 16, 2016·Asian Journal of Andrology·Jonathan Shoag, Christopher E Barbieri
Jul 20, 2016·The New England Journal of Medicine·Colin C PritchardPeter S Nelson
Oct 25, 2016·The Journal of Urology·Hima Bindu MusunuruAndrew Loblaw
Jan 6, 2017·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal

❮ Previous
Next ❯

Citations

Dec 13, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Scott E EggenerHimisha Beltran
Jul 28, 2020·Saudi Journal of Biological Sciences·Chaokai HuChungyu Wu

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy

Software Mentioned

SAS

Related Concepts

Related Feeds

Auditory Perception

Auditory perception is the ability to receive and interpret information attained by the ears. Here is the latest research on factors and underlying mechanisms that influence auditory perception.